Emcure Pharmaceuticals Ltd Financials
Company Logo

Emcure Pharmaceuticals Ltd Financial Statement

Emcure Pharmaceuticals Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Dec 2024
Revenue1055.34
Operating Expense911.51
Net Profit50.20
Net Profit Margin4.76
Earning Per Share2.65
EBIDTA133.31
Effective Tax Rate4.54

Emcure Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual3,497.66
Operating Expenses Annual3,055.76
Operating Profit Annual570.84
Interest Annual166.09
Depreciation189.26
Net Profit Annual160.83
Tax Annual39.08

Emcure Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning-213.05
Cash Flow from Operations584.97
Cash Flow from Investing-173.08
Cash Flow from Financing-287.75
Cash Flow at the End-88.91

Emcure Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)16.32
PBIT Margin (%)10.46
PBT Margin (%)10.40
Net PROFIT Margin (%)4.60
Return On Networth / Equity (%)8.52
Return On Networth /Employed (%)10.08
Return On Assets (%)4.41
Total Debt / Equity (X)0.89
Asset Turnover Ratio (%)0.96

Emcure Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual1,718.24
Total Current Assets Annual2,123.43
Non Current Assets Annual2,633.50
Total Shareholders Funds Annual1,935.10
Total Assets Annual4,756.93

Emcure Pharmaceuticals Ltd Earning Calls

EPS (INR)

Expected

8.11

Reported

8.12

Surprise

0.12%

Sep 2024

EPS beaten by 0.12%

Jun 2024

EPS beaten by -0.58%

Mar 2024

EPS beaten by 0.00%

FAQS on Emcure Pharmaceuticals Ltd Financials

As of Apr 25, 2025, Emcure Pharmaceuticals Ltd has a market capitalization of - Cr. Value Research classifies it as a Micro-Cap company.
No, Emcure Pharmaceuticals Ltd is not debt-free with a debt-to-equity ratio of 0.82.
In FY 2024 , Emcure Pharmaceuticals Ltd recorded a total revenue of approximately 3,497.66 Cr marking a significant milestone in the company's financial performance.
Emcure Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately NaN% and 0.0% annually, respectively..
Emcure Pharmaceuticals Ltd's current PE ratio is undefined.
Emcure Pharmaceuticals Ltd's ROCE averaged 14.4% from the FY ending March 2022 to 2024, with a median of 10.4%. It peaked at 22.4% in March 2022, reflecting strong capital efficiency over the period..
Emcure Pharmaceuticals Ltd's latest EBIT is Rs. 366 Cr, surpassing the average EBIT of Rs. 502.24 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions